Skip to main content
GutCited

Bifidobacterium longum pour Irritable Bowel Syndrome (IBS)

B

RCTs demonstrate significant reduction in IBS composite symptom score versus placebo. Particular benefit for bloating and abdominal distension. Marketed as Alflorex/Align.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dbifidobacterium\u002Dlongum\u0026condition\u003Dibs'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

En conclusion

RCTs demonstrate significant reduction in IBS composite symptom score versus placebo. Particular benefit for bloating and abdominal distension. Marketed as Alflorex/Align.

Key Study Findings

Meta-Analysis n=3154
Comparative effectiveness and safety of probiotics with psychotropic potential in mental health benefits in irritable …
Dose: None vs: placebo Outcome: quality of life, depression, and anxiety in IBS … Effet: SUCRA=89.7% (B. longum for QoL); SUCRA=95.6% (probiotic combo for depression) None

Population: patients with irritable bowel syndrome

Meta-Analysis
Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome.
Dose: None vs: placebo Outcome: improvement in key IBS symptoms Effet: None None

Population: patients with IBS from 32 RCTs evaluating 10 probiotic strains

In Vitro n=35
A Probiotic Mixture of Lactobacillus rhamnosus LR 32, Bifidobacterium lactis BL 04, and Bifidobacterium longum …
Dose: 1e6 CFU/mL vs: IBS supernatants without probiotic Outcome: Caco-2 paracellular permeability Effet: None <0.001

Population: IBS patients (28) and asymptomatic controls (7)

Review
The Role and the Regulation of NLRP3 Inflammasome in Irritable Bowel Syndrome: A Narrative Review.
Dose: None vs: None Outcome: IBS symptom management via NLRP3 inhibition Effet: None None

Population: Patients with IBS (narrative review)

Controlled Clinical Trial n=51 12 weeks Open-label
Targeted probiotic therapy in irritable bowel syndrome: a clinical evaluation on Clostridium butyricum CBM588 and …
Dose: None vs: Pre-treatment baseline Outcome: IBS-SSS score reduction Effet: None None

Population: IBS-D and IBS-C patients

Observational Study n=37 8 weeks Open-label
An 8-Week Course of Bifidobacterium longum 35624® Is Associated with a Reduction in the Symptoms …
Dose: None vs: None Outcome: Total IBS symptom score (TISS) Effet: 43.4% TISS reduction; >60% >=30% responders None

Population: Adults with IBS (Rome IV criteria)

Key Statistics

4

Études

600

Participants

Positive

B

Note

Referenced Papers

Terapevticheskii arkhiv 2023 3 citations
The Cochrane database … 2020 14 citations
Journal of gastroenterology … 2017 32 citations

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Posologies couramment utilisées

general:
1-10 billion CFU/day
ibssupport:
1 billion CFU/day (35624 strain, marketed as Alflorex/Align)

Limite supérieure : Well-tolerated up to 10 billion CFU/day in clinical trials

Posologies étudiées dans la recherche

Posologie Durée Effet N
None -- Positive 3154
None -- Positive --
1e6 CFU/mL -- Positive 35
None -- Positive --
None 12 weeks Positive 51
None 8 weeks Positive 37
1x10^10 CFU daily 6 weeks Positive 35
2 g 4 weeks Mixed --

Moment optimal de prise : On an empty stomach or before meals

Safety & Side Effects

Effets indésirables signalés

  • Mild gas and bloating during initial use
  • Occasional abdominal discomfort
  • Rare loose stools
  • Very rare: bacteremia in immunocompromised individuals

Interactions connues

  • Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
  • Immunosuppressants (use with caution in immunocompromised patients)

Apport maximal tolérable : Well-tolerated up to 10 billion CFU/day in clinical trials

Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.

Frequently Asked Questions

Does Bifidobacterium longum help with Irritable Bowel Syndrome (IBS)?
Based on 4 studies with 600 participants, there is moderate evidence from clinical studies that Bifidobacterium longum may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is B (Good Evidence).
How much Bifidobacterium longum should I take for Irritable Bowel Syndrome (IBS)?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Bifidobacterium longum?
Reported side effects may include Mild gas and bloating during initial use, Occasional abdominal discomfort, Rare loose stools, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Bifidobacterium longum and Irritable Bowel Syndrome (IBS)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 4 peer-reviewed studies with 600 total participants. The overall direction of effect is positive.

Related Evidence

Avertissement FDA: Ces déclarations n'ont pas été évaluées par la Food and Drug Administration. Les produits et informations sur ce site ne sont pas destinés à diagnostiquer, traiter, guérir ou prévenir quelque maladie que ce soit. Les notes de preuve présentées sont basées sur notre analyse de la recherche publiée et évaluée par des pairs et ne constituent pas un avis médical. Consultez toujours votre professionnel de santé avant de commencer tout régime de compléments alimentaires.